论文部分内容阅读
目的:探讨阿帕替尼(Apatinib)对人宫颈癌细胞的抑制增殖作用以及对宫颈癌化疗药物敏感性的影响。方法:CCK-8实验和克隆形成实验分别检测apatinib对宫颈癌细胞Si Ha和HCC94的增殖抑制作用,流式细胞术检测apatinib对宫颈癌细胞周期的影响,RT-qPCR检测Cyclin D3 mRNA表达,Western blot检测Cyclin D3蛋白表达。结果:Apatinib呈剂量依赖性抑制宫颈癌细胞的增殖;apatinib可诱导宫颈癌细胞发生G_0/G_1期阻滞,显著降低宫颈癌Si Ha和HCC94细胞中Cyclin D3 mRNA及Cyclin D3蛋白的表达水平(P<0.01);apatinib可提高宫颈癌细胞对紫杉醇的化疗敏感性。结论:Apatinib可通过诱导宫颈癌细胞G_0/G_1期阻滞抑制其增殖,且对紫杉醇抑制宫颈癌细胞的生长有增效作用。
Objective: To investigate the inhibitory effect of Apatinib on human cervical carcinoma cells and its effect on chemosensitivity of cervical cancer. Methods: The inhibitory effects of apatinib on the proliferation of cervical cancer cells Si Ha and HCC94 were detected by CCK-8 assay and colony formation assay respectively. The effect of apatinib on the cell cycle of cervical cancer cells was detected by flow cytometry. The expression of Cyclin D3 mRNA was detected by RT-qPCR. blot detection of Cyclin D3 protein expression. Results: Apatinib inhibited the proliferation of cervical cancer cells in a dose-dependent manner. Apatinib induced the arrest of G 0 / G 1 phase in cervical cancer cells and significantly decreased the expressions of Cyclin D3 mRNA and Cyclin D3 protein in Si Ha and HCC94 cells (P <0.01). Apatinib can enhance chemosensitivity to paclitaxel in cervical cancer cells. CONCLUSION: Apatinib can inhibit the proliferation of cervical cancer cell line G_0 / G1 and inhibit the growth of cervical cancer cell line paclitaxel.